Is Additional Treatment Needed Pretransplant in R/R AML? : v

Experts recently debated whether additional intensive therapy can improve posttransplant outcomes for patients with acute myeloid leukemia who have residual disease after induction therapy.

Related Keywords

Miami , Florida , United States , Texas , Houston , American , Fred Hutchinson , Mikkaela Sekeres , Johannes Schetelig , Ronaldb Walter , University Of Miami Miller School Medicine , Fred Hutchinson Cancer Research Center , Astrazeneca , American Society Of Hematology , Society Of Hematologic Oncology , Hematologic Oncology , Clinical Trials Unit , Miami Miller School , American Society , Complete Remission , Annual Meeting , Acute Leukemia , Transplantation Stem Cell , Ransplantation Hematopoietic Stem Cell , Hematopoietic Stem Cell Transplantation , Stem Cell Transplantation , Stem Cell Therapy , Herapy Stem Cell , Transplantation , Transplant , Remission , Allograft , Residual Disease , Acute Myeloblastic Leukemia , Myelodysplastic Syndrome , Ads , Leukemia , Refractory , Toxicology ,